Rabbit Recombinant Monoclonal APOBEC3G/A3G antibody. Carrier free. Suitable for IP, IHC-P, WB and reacts with Human, Transfected cell line - Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
IP | Flow Cyt (Intra) | ICC/IF | IHC-P | WB | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Tested | Tested |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Transfected cell line - Human | Not recommended | Not recommended | Not recommended | Not recommended | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat, Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Rat | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Transfected cell line - Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Transfected cell line - Human, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms (PubMed:12808465, PubMed:16527742, PubMed:17121840, PubMed:18288108, PubMed:18849968, PubMed:19153609, PubMed:21123384, PubMed:22791714, PubMed:25542899). Exhibits potent antiviral activity against Vif-deficient HIV-1 (PubMed:12167863, PubMed:12859895, PubMed:14557625, PubMed:20219927, PubMed:21835787, PubMed:22807680, PubMed:22915799, PubMed:23097438, PubMed:23152537, PubMed:31397674). After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA (PubMed:12808465, PubMed:12808466, PubMed:12809610, PubMed:12970355, PubMed:14528300, PubMed:22807680). The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells (PubMed:12808465, PubMed:12808466, PubMed:12809610, PubMed:12970355, PubMed:14528300). Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA (PubMed:12808465, PubMed:12809610, PubMed:12970355, PubMed:14528300). Exhibits antiviral activity also against simian immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV) (PubMed:15031497, PubMed:16378963, PubMed:18448976, PubMed:19458006, PubMed:20335265). May inhibit the mobility of LTR and non-LTR retrotransposons (PubMed:16527742).
MDS019, APOBEC3G, DNA dC->dU-editing enzyme APOBEC-3G, APOBEC-related cytidine deaminase, APOBEC-related protein 9, CEM-15, Deoxycytidine deaminase, APOBEC-related protein, ARCD, ARP-9, CEM15, A3G
Rabbit Recombinant Monoclonal APOBEC3G/A3G antibody. Carrier free. Suitable for IP, IHC-P, WB and reacts with Human, Transfected cell line - Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
APOBEC3G also known as A3G is an enzyme that belongs to the APOBEC family of cytidine deaminases. It has a molecular mass of approximately 46 kDa. This protein is expressed in various tissues including immune cells like lymphocytes and macrophages. A3G plays a mechanical role in catalyzing the deamination of cytidine to uridine on single-stranded DNA which impacts the genetic material of retroviruses.
APOBEC3G acts as a host defense mechanism against retroviral infections particularly HIV-1. It incorporates into budding virions where it exerts its antiviral effect. A3G functions within the APOBEC protein family complex that participates in innate immunity. This antiviral activity helps to inhibit viral replication by inducing lethal mutations in the viral genome.
APOBEC3G is vital in the HIV-1 life cycle disruption pathway. It interacts with other cellular factors such as the viral protein Vif which counters APOBEC3G’s activity by targeting it for proteasomal degradation. The protein is also involved in the regulation of gene expression pathways linked to innate immune responses.
APOBEC3G is associated with HIV-1 infection. Elevated levels of APOBEC3G can lead to the hypermutation of viral DNA potentially reducing viral loads in host cells. The protein’s interaction with HIV-1 Vif protein is critical as Vif facilitates the degradation of A3G allowing the virus to escape its antiviral activity. Additionally researchers investigate a possible connection between A3G and cancer due to its mutation-inducing capability in DNA.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
This antibody does not cross-react with human APOBEC3A or APOBEC3B
Exposure time: 180 seconds
All lanes: Western blot - Anti-APOBEC3G/A3G antibody [EPR25404-59] (Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926) at 1/1000 dilution
Lane 1: 293T transfected with human APOBEC3G expression vector containi a myc-His-tag®, whole cell lysate, 20 μg
Lane 2: 293T transfected with human APOBEC3A expression vector containi a myc-His-tag®, whole cell lysate, 20 μg
Lane 3: 293T transfected with human APOBEC3B expression vector containi a myc-His-tag®, whole cell lysate, 20 μg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 42 kDa
Exposure time: 180s
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Exposure time: 180 seconds
All lanes: Western blot - Anti-APOBEC3G/A3G antibody [EPR25404-59] (Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926) at 1/1000 dilution
Lane 1: Human tonsil tissue lysate 20 μg
Lane 2: Human heart tissue lysate 20 μg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Observed band size: 42 kDa
Exposure time: 180s
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
APOBEC3G/A3G was immunoprecipitated from 0.35 mg H9 (human lymphoma T lymphocyte) whole cell lysate 20 ug with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: H9 whole cell lysate 20 ug
Lane 2: Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 IP in H9 whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 in H9 whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 15 seconds.
All lanes: Immunoprecipitation - Anti-APOBEC3G/A3G antibody [EPR25404-59] (Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926) at 1/1000 dilution
Lane 1: H9 (human lymphoma T lymphocyte), whole cell lysate 20 μg
Lane 2: H9, whole cell lysate
Lane 3: Immunoprecipitation - Rabbit IgG, monoclonal [EPR25A] - Isotype Control (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730)
All lanes: Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/5000 dilution
Observed band size: 42 kDa
Exposure time: 15s
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Negative control: Jurkat (PMID: 14527406)
Exposure time: 180 seconds
All lanes: Western blot - Anti-APOBEC3G/A3G antibody [EPR25404-59] (Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926) at 1/1000 dilution
Lane 1: H9 (human lymphoma T lymphocyte), whole cell lysate 20 μg
Lane 2: Jurkat (human T cell leukemia T lymphocyte), whole cell lysate 20 μg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 42 kDa
Exposure time: 180s
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded wild-type H9 cell pellet labeling APOBEC3G/A3G with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 at 1/2000 (0.255 ug/ml) followed by ready to use LeicaDS9800 (Bond® Polymer Refine Detection).
Positive staining on wild-type H9 cell pellet (Panel A); No staining on wild-type Jurkat cell pellet (Panel B); No staining on wild-type 293T cell pellet (Panel C). The section was incubated with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is ready to use LeicaDS9800 (Bond® Polymer Refine Detection).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins.
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded human breast cancer tissue labeling APOBEC3G/A3G with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 at 1/2000 (0.255 ug/ml) followed by ready to use LeicaDS9800 (Bond® Polymer Refine Detection).
Positive staining on immune cells in human breast cancer.
The section was incubated with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is ready to use LeicaDS9800 (Bond® Polymer Refine Detection).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins.
This data was developed using Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926, the same antibody clone in a different buffer formulation.
Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling APOBEC3G/A3G with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 at 1/2000 (0.255 ug/ml) followed by ready to use LeicaDS9800 (Bond® Polymer Refine Detection).
Positive staining on immune cells in human tonsil.
The section was incubated with Anti-APOBEC3G/A3G antibody [EPR25404-59] ab302926 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control: Secondary antibody is ready to use LeicaDS9800 (Bond® Polymer Refine Detection).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com